Z6尊龙
Other Affiliated Sites
Techdow Pharma China
Techdow Pharma UK
Techdow Pharma Poland
Techdow Pharma Italy
Techdow Pharma Spain
Techdow Pharma Germany
Techdow Pharma US
Cytovance Biologics
SPL
Simplified Chinese
Traditional Chinese
About Hepalink
Group Profile
Corporate Philosophy
Milestones
Leadership Team
Scientific Advisory Board
Our Businesses
Heparin Business
Global Industrial Chain
Global Heparin Injections Business
Product Profile
CDMO Services
Innovative Drugs
Global Manufacturing
Company News
Investor Relations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Join Us
Career Development
Job Opportunities
Campus Recruitment
Contact Us
Create Value for Investors Through
Safe and Stable Operations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Disclosures
A-Share Information
H-Share Information
Financial Reports
Announcements
2012.02.11
自力董事果真征集委托投票权报告书
2012.01.14
关于证监会确认股权激励妄想(草案)无异议并备案的通告
2012.01.11
关于控股子公司完成增资工商变换挂号的通告
2012.01.10
关于控股股东完成增持公司股份的通告
2011.12.21
关于对控股子公司举行增资的通告
2011.12.21
关于内部控制规则落真相形整改完成的通告
2011.12.21
第二届董事会第十次聚会决议通告
2011.12.21
股票期权激励妄想(草案)
2011.12.21
股票期权激励妄想(草案)摘要
2011.12.21
北京市中伦状师事务所关于公司股权激励妄想的执法意见书
第一页
上一页
133
134
135
136
137
下一页
最后一页
About Hepalink
Group Profile
Corporate Philosophy
Milestones
Leadership Team
Scientific Advisory Board
Our Businesses
Heparin Business
CDMO Services
Innovative Drugs
Global Manufacturing
Company News
Investor Relations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Join Us
Career Development
Job Opportunities
Campus Recruitment
Contact Us
Official WeChat Account
Legal Statement
·
Environmental Disclosure
Copyright ? 2024 Hepalink Group. All Rights Reserved.
【网站地图】
【sitemap】